PROCESS FOR PRODUCING RADIOLABELLED BENZODIAZEPINE RECEPTOR AGENTS AND COMPOSITION CONTAINING THE SAME

Abstract: A process for producing a carrierfree radiohalogenated 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5,6-dihydro-5-methyl-6-oxo-4H-i midazo[1,5-a][1,4]-benzodiazepine of formula (II) where R<1> is a radioactive halogen and R<1> may be at 7, 8, 9, or 10 substituent. The above compound is used in a pharmaceutical composition for nuclear medicine examination.

Description: PROCESS FOR PRODUCING RADIOLABELLED BENZODIAZEPINE RECEPTOR AGENTS AND COMPOSITION CONTAINING THE SAME. Technical field The present invention relates to a process for producing radioactive substiruted benzodiazepines and to pharmaceutical compositions containing said benzodiazepines. Background art Radiolabelled compounds which are subject to localization in particular organs or tumors therein are of great value for the diagnosis of diseases of the human body. For example, iodine-123 labelled fatty acids and thallium-201 have been utilized as heart imaging agents. Various isonitrile ligands labelled with technetium-99m have been used to image infarcted regions on the heart. Substituted benzodiazepines, which are labelled with iodine- 123, iodine- 125 or iodine- 131 have been used for studies of benzodiazepine receptors in the brain. A new benzodiazepine receptor ligand fradioiodine] 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl) -7-iodo-5.6-dihydro-5-methyl-6-oxo-4H-imidazo[l,5-a][l,4]-benzodiazepine was introduced recently (C. Foged et al. , J. Nucl Med. 1993: 34, p89). The common preparation scheme for radioiodined carrier free neuroreceptor ligands employs a trialkyltin precursor and radioactive iodine by the chloramin-T method in strongly acidic conditions. However the labelling reaction is associated with a large and consistent formation of a radioactive volatile reaction product: methyliodine (Y. Zea-Ponce et al.. J. Lab. Comp. Rad. 1994: 36, 331-337). The side reaction products may contain up to 60% of the activity that is added into the reaction mixture. The loss of that amount of the activity increases production costs tremendously. An another disadvantage, which results from the formation of methyliodine. is radio protection costs and problems. The high increase of the required radioactivity increases the need for radioprotection of persons in the very early moments during upscaling the process. Another radioprotection problem resides in the need to catch up methyliodine. Active charcoal filters, which are used to capture radioiodine from the air. do not hold methyliodine. It requires special reactor grade active charcoal filters that are another source of extra expenses. Disclosure of the invention To avoid the radioactive volatile by-product of the prior an we found an alternative route to produce [radiohalogenated] 3-(5-cyclopropyl-l ,2,4-oxadiazol-3-yl)-5,6-dihydro-5-methyl-6- oxo-4H-imidazo[l ,5-a][l ,4]-benzodiazepine (II). wherein R' is a radioactive halogen at position 7, 8, 9 or 10. Said radioactive halogen is preferably 123 I, 124 I, 125 I, 131 I. Other suitable radioactive halogens are F 18 . Br 75 , Br 76 , Br 77 . The present invention is directed to a process for producing carrier free [radiohalogen] 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[l ,5-a][1.4]- benzodiazepine using a halogenated precursor and HPLC purification with a high yield. The present invention is also directed to a pharmaceutical composition containing said radiohalogenated benzodiazepine. The process according to the present invention is defined in the appended claims. As described below, radioiodine is used as a non limiting example of radiohalogens. According to the present invention formation of the radioactive methyliodine is avoided and the yield of the labelled benzodiazepine increases. It is known that one can easily exchange a halogen on the benzene ring into another one having a lower atom number. In the opposite direction the reaction is rather slow and normally yields a poor result. Neuroreceptor imaging agents are required to be carrier free. The above mentioned exchange process results in a product having a carrier, where precursor and radiolabelled product are difficult to separate from each otiier. The pharmaceutical composition according to the invention contains an effective amount of the compound (II) and a pharmaceutically acceptable liquid carrier material and optionally one or more pharmaceutically acceptable adjuvants. It is suitable for use as a benzodiazepine receptor imaging agent. In such medical use the radiohalogenated benzodiazepine is carrier free and an effective dose of the radiohalogenated benzodiazepine is generally about 20 to 1100 MBq preferably 37 to 370 MBq. In the prior art processes the active ingredient in the final pharmaceutical composition binds to the walls of the glass vial. To prevent this unwanted binding on me walls of the glass vial, a solvent is added to the compound according to the present invention. The preferred solvents are such as ethanol, PEG, propy leneglycol, Tween or mixtures which contain two or more solvents, more preferably 1 to 20 % by weight of ethanol. In one embodiment of the present invention a preferred synthesis route comprises one wherein the halogen of 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-7-bromo-5.6-dihydro-5 methyl-6-oxo-4H-imidazo[1.5-a][l,4]-benzodiazepine is exchanged into radioactive iodine or the halogen of 3-(5-cyclopropyl-l,2.4-oxadiazoI-3-yl)-7-iodo-5,6-dihydro-5- met hyl-6-oxo-4H-imidazo[l,5-a][l,4]-benzodiazepine is exchanged into radioactive bromine or fluorine. The process is run at an elevated temperature and in a halogen-free acidic medium. The preferred temperature is 100 β C to 250°C more preferably 130°C to 200°C most preferably 150-180°C. The radiolabelled compound is separated from the precursor using chromatographic methods. The preferred chromatographic method is HPLC and using a reversed phase column. The mobile phase comprises polar and nonpolar solvents. The preferred mobile phase comprises 0.5:5 to 1:0.5 aqueous triethylamine and acetonitrile: It is more preferable that the mobile phase comprises 1:3 to 2:3 of 0.1-0.5 % aqueous triethylamine (pH 3.5-9.5) and acetonitrile. Chart 1 R = halogen R' = radioactive halogen Experimental The following experiments illustrate the invention, but they are not to be constructed as limiting the invention. Example 1 Synthesis of [ 12 5τ] 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-7-iodo-5,6-dihydro-5- methyl-6-oxo-4H-imidazo[l,5-a][l,4]-benzodiazepine by replacing bromine with radioiodine starting from the bromo precursor 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)- 7-brorno-5,6-dihydro-5-methyl-6-oxo-4H-i midazo[l,5-a][l, 4] -benzodiazepine Nal25 (37 MBq in lOμl) was dried in a gentle flow of nitrogen. 3-(5-cyclopropyl-l ,2,4-oxadiazol-3-yl)-7-bromo-5,6-dihydro-5-methyl-6-oxo-4H-imi- dazo[1.5-a][l ,4]-benzodiazepine in acetic acid (lmg in 200 μl) was added to vial. The vial was heated at 150°C for one hour. The acetic acid was then evaporated in a nitrogen flow and the residue was dissolved in a mobile phase (1 ml) and injected onto a HPLC μ-Bondapak-C-18 column. The mobile phase was 0.2% aqueous triethylamine (pH =7) and acetonitrile (3:5). The l^^I-labelled product eluted with a retention time identical to that of a non-radioactive standard reference sample. The yield after purification was 45 %, with a radiochemical purity of > 98% . Example 2 Synthesis of [123 j ι 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-7-iodo-5,6-dihydro-5-methyl- 6-oxo-4H-imidazo[l,5-a][l ,4]-benzodiazepine by replacing bromine with radioiodine starting from the bromo precursor 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-7-bromo-5,6-dihydro-5- mefhyl-6-oxo-4H-i midazo[l,5-a][l , 4]-benzodiazepine Na 123 I (2200 MBq in 200μl) was dried in a gentle flow of nitrogen. 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-7-bromo-5,6-dihydro-5-methyl-6-oxo-4H- imidazo[ 1 ,5 -a] [1 ,4] -benzodiazepine in acetic acid (0.35 mg in 70 μl) was added to a vial. The vial was heated at 160°C for one and a half hours. The acetic acid was then evaporated and the residue was dissolved in a mobile phase (1 ml) and injected onto a HPLC μ-Bondapak-C-18 column. The mobile phase was 0.2% aqueous triethylamine (pH = 7) and acetonitrile (2:3). The l^I-labelled product eluted with a retention time identical to that of a non-radioactive standard reference sample. The yield after purification was 75-80% . with a radiochemical purity of > 98% . Example 3 The effect of the reaction temperature on the yield of iodine-123 labelled benzodiazepine Example 2 was repeated to provide labelling as mentioned above except that the vial was heated to different temperatures as indicated in Table 1 below. The yield of labelled product was measured and the results are indicated in Table 1. Table 1. Effect of the reaction temperature Temperature °C [I-123]-benzodiazepine yield % 100 10 150 40 165 80 200 70 250 60 The above experiment shows that an elevated temperature provides an increase in the yield of the radiolabelled benzodiazepine. Example 4 The effect of solvents on the activity of the product The procedures of example 2 were repeated to provide labelled [ 123 I]3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-7-iodo-5,6-dihydro-5-methyl-6-oxo-4H-imi- dazo[l ,5-a][l ,4]-benzodiazepine using a bromo precursor as described above. The resulting compounds were used to provide final pharmaceutical compositions using pharmaceutically acceptable buffers and solvents and 9 mg/ml sodium chloride as diluent. The product was incubated in a 10 ml glass vial over 24 hours. The labelled [^ 23 I] benzodiazepine was drawn off. The residue activity in the vial was measured to find out how much of the reaction product had been bound to the glass walls of the vial. The procedure was repeated with different solvents and the results are disclosed in Table 2 below. The final concentration of the solvent must be pharmaceutically acceptable. Table 2 Solvent Residue activity % of total activity none 20-35 ethanol 5-10 glucose 10-20 Tween 5-15 PEG 5-15 glycerol 5-15 propylene glycol 5-10 ethanol-propylene 5-10 30-70 The experiments indicate that the use of suitable solvents will reduce the amount of compound bound to the walls of the reaction vessel and the product vial and therefore increase the over-all yield of the process. Example 5 Formulation of a pharmaceutical composition The procedures of example 2 were repeated to provide labelled [123i]3_(5 . C y C ι 0 p ro pyi-i ι 2,4-oxadiazol-3-yl)-7-iodo-5,6-dihydro-5-methyl-6-oxo- 4H-imidazo[l ,5-a][l ,4]-benzodiazepine using a bromo precursor as described above. The resulting compounds were used to provide final pharmaceutical compositions using pharmaceutically acceptable buffers to get a final pH of 4.5 to 10 and solvents and 9 mg/ml sodium chloride as diluent. The following pharmaceutical composition was produced iodine 123-benzodiazepine 185 MBq active ingredient ethanol 94% 0.5 ml solvent 0, 18M NaH PO4/Na 2 HPO 4 pH 7 0.2 ml buffer 9 mg/ml NaCI 4.3 ml diluent The present invention has been described above with a reference to specific radiohalogenated benzodiazepines. A person skilled in the art will know, however, that similar procedures may be used to provide the other radiohalogenated compounds of the present invention.

Claims: Claims 1. A process for producing a radiohalogenated 3-(5-cyclopropyl- l,2,4-oxadiazoI-3-yl ) -5,6-dihydro-5-methyl-6-oxo-4H-imidazo[l ,5-a][l,4]-benzodiazepine characterized in that a precursor of the general formula (I) wherein R is bromine or iodine and R may be a 7, 8, 9, or 10 substituent, is converted into a radiohalogenated 3-(5-cyclopropyl-l,2,4-oxadiazol-3-yl)-5,6-dihydro-5-methyl-6-o xo-4H- imidazo[l ,5-a][ 1 ,4] -benzodiazepine of the general formula wherein R^is a radioactive halogen, selected from radioactive iodine, radioactive bromine, radioactive fluorine and R may be a 7, 8, 9 or 10 substituent, by performing a radiohalogenisation reaction comprising exchanging the inactive halogen of the precursor (I) into a radioactive halogen at an elevated temperature in a halogen- free acidic medium, whereafter the end product (II) is separated from the precursor (I) by using chromatographic methods. 2. A process for producing a radiohalogenated compound (II) according to claim 1 wherein said temperature is 100°C to 250°C, more specifically the temperature is 130°C to 200°C, especially 150°C to 180°C. 3. A process for producing a radiohalogenated compound (II) according to any one of claims 1 or 2 wherein said chromatographic method is HPLC. 4. A process for producing a radiohalogenated compound (II) according to any one of claims 1 to 3 wherein said chromatographic method is HPLC and a reversed phase column is used, the mobile phase comprising polar and nonpolar solvents, such as a 0.5:5 to 1 :0.5 mixture of aqueous triethylamine and acetonitrile, especially 1 :3 to 2:3 of 0.1-0.5 % aqueous triethylamine (pH 3.5-9.5) and acetonitrile. 5. A process for producing a radiohalogenated compound (II) according to any one of claims 1 ro 4 wherein said radioactive halogen is radioiodine, more specifically radioactive halogen is iodine- 123. 6. A process for producing a radiohalogenated compound (II) according to any one of claims 1 to 5 wherein said inactive halogen is bromine. 7. A process for producing a radiohalogenated compound (II) according to any one of claims 1 to 6 wherein said radiohalogenated compound is radiolabelled 3-(5-cyclopropyl-l ,2.4-oxadiazol-3-yl)-7-halogen-5,6-dihydro-5- methyl-6-oxo-4H - imidazo [ 1 , 5-a] [ 1 , 4] -benzodiazepine . 8. A pharmaceutical composition containing radiohalogenated 3-(5-cyclopropyl- 1 ,2,4- oxadiazol-3-yl)-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[l ,5 -a] [1,4] -benzodiazepine of the general formula. d) wherein a radioactive halogen, selected from radioactive iodine, radioactive bromine, radioactive fluorine and Rl may be 7, 8, 9 or 10 substituent, and a pharmaceutically acceptable liquid carrier material and optionally one or more pharmaceutically acceptable adjuvants 9 A pharmaceutical composition according to claim 8 comprising an effective amount of a compound (II) and a solvent, such as ethanol, PEG, propy leneglycol, Tween or a mixture which contain two or more of said solvents, 1 to 20 % by weight of ethanol 10 A pharmaceutical composition according to claim 9 suitable for nuclear medicine examination wherein the compound (II) is produced according to any one of the claims 1 to 7

Inventors: FARDE LARS, FOGED CHRISTIAN, HALLDIN CHRISTER, HILTUNEN JUKKA, FARDE, LARS, FOGED, CHRISTIAN, HALLDIN, CHRISTER, HILTUNEN, JUKKA
Applicants: FARDE LARS, FOGED CHRISTIAN, HALLDIN CHRISTER, HILTUNEN JUKKA, MAP MEDICAL TECHNOLOGIES OY, FARDE, LARS, FOGED, CHRISTIAN, HALLDIN, CHRISTER, HILTUNEN, JUKKA
Application year: 1997
Main classification: C07D487
IPC codes: A61K51, C07D487